Damora Therapeutics, Inc. (DMRA) Stock Price & Analysis
Damora Therapeutics, Inc. (DMRA) fell 1.20% to USD 28.82 as of July 25, 2026 at 11:58 UTC, according to Nexqual real-time market data.
DMRA last closed at USD 29.17; the session ranged USD 28.48–30 on volume of 546,457 shares. Market capitalization is $1.77B, with a 52-week range of USD 2.45–38.33 (NCM). Source: Nexqual, July 25, 2026 at 11:58 UTC.
Key Statistics (as of July 25, 2026 at 11:58 UTC)
| Price | USD 28.82 |
|---|---|
| Change | ▼ 1.20% (down) |
| Previous Close | USD 29.17 |
| Open | USD 29.79 |
| Day Range | USD 28.48 – 30 |
| 52-Week Range | USD 2.45 – 38.33 |
| Volume | 546,457 shares |
| Market Cap | $1.77B |
| Exchange | NCM |
Technical Analysis (DMRA)
Nexqual's technical model rates DMRA "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 11:58 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.23 (neutral) |
| vs SMA50 | Above (USD 25.48) |
| MACD | 1.59 (positive) |
Analyst Ratings (DMRA)
Wall Street analysts rate DMRA "Strong Buy" based on 8 analysts, with a mean price target of USD 43.38 (range USD 35–51), per Nexqual as of July 25, 2026 at 11:58 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 43.38 |
| High Target | USD 51 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (DMRA)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.37 |
| Revenue Estimate | $0 |
Source: Nexqual, July 25, 2026 at 11:58 UTC.
Financials & Fundamentals (DMRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -89.50% |
| Current Ratio | 22.49 |
| Total Cash | $532.90M |
| Total Debt | $0 |
| Free Cash Flow | $-8.69M |
Source: Nexqual, July 25, 2026 at 11:58 UTC.
Financial Health Score (DMRA)
Nexqual rates Damora Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 11:58 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $533M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$25M |
| Efficiency | Critical — ROE -90%, ROA -14.7% |
Ownership (DMRA)
| Insider Ownership | +7.62% |
|---|---|
| Institutional Ownership | +94.11% |
| Shares Outstanding | 61.55M |
| Float | 41.22M |
| Short % of Float | +8.90% |
Source: Nexqual, July 25, 2026 at 11:58 UTC.
Leadership (DMRA)
Damora Therapeutics, Inc. is led by Jennifer A. Jarrett (age 54), CEO, President & Director, per Nexqual as of July 25, 2026 at 11:58 UTC.
| CEO, President & Director | Jennifer A. Jarrett (age 54) |
|---|---|
| Chief Operating Officer | Sherwin Sattarzadeh (age 46) |
Major Backers & Investors (DMRA)
Notable institutional backers of Damora Therapeutics, Inc. include FMR, LLC, Fairmount Funds Management LLC, Fidelity, according to Nexqual as of July 25, 2026 at 11:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.7% |
| Fairmount Funds Management LLC | 14.16% |
| Fidelity | 9.31% |
| Avoro Capital Advisors LLC | 6.15% |
| Venrock Adviser, LLC | 5.85% |
| FCPM III Services B.V. | 3.97% |
| RA Capital Management, L.P. | 3.9% |
| Janus Henderson Group PLC | 3.84% |
Source: Nexqual, July 25, 2026 at 11:58 UTC.
From Damora Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.
- The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
- It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PRAX | Praxis Precision Medicines, Inc | USD 325.3 | ▲ 4.23% |
| OLMA | Olema Pharmaceuticals, Inc. | USD 11.7 | ▲ 1.83% |
| CYCN | Cyclerion Therapeutics, Inc. | USD 3.5 | ▼ 3.58% |
| EVAX | Evaxion A/S | USD 2.96 | ▼ 2.63% |
| PRFX | PRF Technologies Ltd. | USD 1.14 | ▼ 5.42% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 11:58 UTC. This page is informational and not investment advice.